Evaluation of four different fecal tests for determination of cure after Helicobacter pylori treatment

Abstract

Background: Data evaluating the monoclonal tests for determination of cure after Helicobacter pylori treatment are scarce.

Goals: This study was aimed to evaluate the usefulness of 4 stool tests-2 new RAPID monoclonal immunochromatographic tests (RAPID Hp StAR, DakoCytomation, Cambridge, UK and ImmunoCard STAT! HpSA, Meridian Diagnostics, Cincinnati, OH) a monoclonal EIA test (Amplified IDEIA Hp StAR, DakoCytomation, Cambridge, UK), and a polyclonal EIA test (Premier Platinum HpSA, Meridian Diagnostics, Cincinnati, OH)-to confirm cure of H. pylori infection after eradication treatment.

Study: Ninety-seven patients who underwent eradication treatment were included. Cure of H. pylori infection was determined using 2 consecutive reference tests. Fecal tests were performed according to the specifications of the manufacturer. Sensitivity, specificity, and positive and negative predictive values were calculated.

Results: After H. pylori eradication, the RAPID Hp StAR test has a sensitivity of 73% for detecting persistent infection, a specificity of 96% to 98%, a positive predictive value of 73% to 80% and a negative predictive value of 96%. For ImmunoCard STAT! HpSA the corresponding values were 91%, 97%, 77%, and 99%, for Amplified IDEIA Hp StAR 73%, 97%, 73%, and 97%, and for Premier Platinum HpSA 91%, 79%, 35%, and 98%.

Conclusions: All tests except Premier Platinum HpSA were highly accurate confirming eradication after treatment.